Targets › PHF8
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Aug 2027.
Histone lysine demethylase with selectivity for mono- and dimethylated residues. It plays an essential role in cell cycle progression and rDNA transcription. (UniProt, Q9UPP1)
Open in Phaseline: the race on PHF8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| InSilico Medicine Hong Kong | ISM5411 (Garutadustat) PHF8 inhibitor | PHF8 | Phase 2 | Ulcerative Colitis | Aug 2027 |
Ulcerative Colitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.